ALS Drug Prosetin Hits Safety Milestones in Phase 1b Trial Enrollment
ProJenX completes enrollment for Prosetin's Phase 1b ALS trial, reporting strong safety data and target engagement at therapeutic doses.
Summary
ProJenX has completed enrollment for its Phase 1b clinical trial of Prosetin, an investigational drug targeting ALS. The trial included 41 participants across five dose levels. Interim data show Prosetin was safe and well tolerated, with no serious drug-related adverse events. At the two highest doses, blood plasma levels reached the therapeutic range predicted by preclinical models. Crucially, the drug showed measurable target engagement — it reduced a specific protein marker in immune cells, confirming the drug is hitting its intended biological target. Participants can now enter a two-year extension study to assess long-term safety and track biomarkers like neurofilament light chain, a key indicator of nerve damage. Full interim results will be presented at a major ALS conference in Madrid in late June 2026.
Detailed Summary
ALS, or amyotrophic lateral sclerosis, is a fatal neurodegenerative disease with very limited treatment options. Any new drug showing early safety and biological activity in human trials represents meaningful progress for patients and researchers alike. ProJenX's Prosetin targets MAP4K, a kinase pathway implicated in neuronal stress and death, making it a mechanistically novel approach compared to existing ALS therapies.
The Phase 1b trial, known as Pro-101, has now completed its multiple ascending dose phase with 41 participants tested across five increasing dose levels. The key finding is that Prosetin appears safe at all tested doses, with no serious adverse events attributed to the drug. This clears a critical hurdle for any investigational compound moving toward larger efficacy trials.
Beyond safety, the trial demonstrated proof-of-mechanism. At the two highest doses — 0.70 and 1.05 mg/kg per day — plasma drug concentrations reached the therapeutic exposure range set by preclinical models. Importantly, treatment produced a statistically significant, dose-dependent reduction in phosphorylated MAP2K4 in peripheral blood cells, confirming the drug is engaging its intended molecular target in humans.
Participants are now eligible to enroll in a two-year open-label extension. This phase will monitor long-term safety and track exploratory biomarkers including neurofilament light chain, a widely used blood marker of neurodegeneration, as well as functional outcomes. These data will be critical for determining whether biological target engagement translates into meaningful clinical benefit.
Caveats are important here. This is still an early-phase trial focused primarily on safety and pharmacology, not efficacy. Prosetin is not FDA-approved and remains investigational. Larger randomized controlled trials will be needed to determine whether this promising early signal translates into slowed disease progression or improved survival for ALS patients.
Key Findings
- Prosetin showed no serious drug-related adverse events across all five dose levels in 41 ALS participants.
- Therapeutic plasma concentrations were achieved at the two highest doses, validating preclinical dosing models.
- Drug significantly reduced phosphorylated MAP2K4 in blood cells, confirming on-target biological activity in humans.
- A two-year open-label extension will track neurofilament light chain and functional outcomes long-term.
- Interim results will be publicly presented at the European Network to Cure ALS meeting in Madrid, June 2026.
Methodology
This is a news report summarizing a company-issued development update, not a peer-reviewed publication. The source, Longevity.Technology, is a credible longevity-focused outlet, but the data cited come directly from ProJenX without independent verification. Interim trial results have not yet been published in a journal.
Study Limitations
Data are from a company press update, not a peer-reviewed publication, so independent scrutiny is pending. The trial is designed to assess safety and pharmacology, not efficacy — no functional benefit in ALS patients has been demonstrated yet. Clinicians and patients should await full published results and future Phase 2 efficacy data before drawing conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.